Categories: HealthcareNews

Connecticut Proton Therapy Center selects RayCare

STOCKHOLM, Aug. 21, 2024 /PRNewswire/ — RaySearch Laboratories AB (publ) is pleased to announce that the Connecticut Proton Therapy Center, Wallingford, Connecticut, USA, has placed an order for the oncology information system RayCare®*.

The Connecticut Proton Therapy Center will be the first of its kind in the state of Connecticut and is a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International. The center has selected RayCare and the IBA Proteus®ONE compact proton therapy system as its treatment platform.

RayCare will be Connecticut Proton Therapy Center’s only oncology information system and will be utilized with the ProteusONE proton system. The center will use the workflow engine of RayCare for creating clinic specific workflows, with the aim of a complete clinical implementation in 2026, when the center opens. RayCare will also be used together with RaySearch’s treatment planning system RayStation, which was acquired in 2023.

Johan Löf, founder and CEO, RaySearch, says: “We are happy to welcome yet another RayCare customer. For our installed base of RayStation customers the selection of RayCare as oncology information system will enhance efficiency and user experience, both in the treatment planning process and treatment delivery.”

Revenue from the order is expected to be recognized during 2025.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

* Subject to regulatory clearance in some markets.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/connecticut-proton-therapy-center-selects-raycare,c4026538

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/connecticut-proton-therapy-center-selects-raycare-302227390.html

SOURCE RaySearch Laboratories

Staff

Recent Posts

Windtree Therapeutics Announces New Corporate Strategy Seeking to Identify and Acquire FDA-Approved Revenue Assets While Advancing Its Cardiovascular and Oncology Pipeline

All-Stock Acquisition Strategy Targets Multiple Small Companies with FDA-Approved Products to Drive Growth and Shareholder…

5 seconds ago

Microbot Medical Announces $8.6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

HINGHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) today announced…

7 seconds ago

Noema Pharma Appoints Michael Samar as Chief Financial Officer

Appointment Further Strengthens Leadership Team; Follows Appointment of Volker Knappertz, M.D., as Executive Vice President…

19 seconds ago

Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025

NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”…

27 seconds ago